Neisseria meningitidis serogroup C polysaccharide-protein conjugate (None established in the scientific literature for this specific conjugate antigen; abbreviations typically refer to the vaccine formulation (e.g., MenC, MenC-conjugate), not to the polysaccharide conjugate itself[1][2][5]. MenC is used in the context of the vaccine, not as molecular nomenclature.)

Neisseria meningitidis serogroup C polysaccharide-protein conjugate is an antigenic complex used in meningococcal vaccines to prevent disease caused by Neisseria meningitidis serogroup C. The antigen consists of a purified capsular polysaccharide from serogroup C bacteria covalently attached to a carrier protein (commonly a nontoxic mutant of diphtheria toxin, CRM197). This conjugation significantly enhances immunogenicity, especially in young children, by enabling T cell-dependent immune responses that result in strong and long-lasting protective antibody titers and immune memory. This type of vaccine has replaced plain polysaccharide formulations in most immunization programs due to its superior efficacy and ability to induce herd immunity through reduction of nasopharyngeal carriage[1][2][5].

Other names

Meningococcal serogroup C polysaccharide-protein conjugateMenC conjugate antigenNeisseria meningitidis group C conjugate

Induces a T cell-dependent immune response by presenting the polysaccharide conjugated to a carrier protein (such as diphtheria toxoid CRM197)[1]. Stimulates formation of bactericidal antibodies specifically targeting the serogroup C capsular polysaccharide of Neisseria meningitidis[2][1]. Reduces nasopharyngeal carriage and transmission, contributing to herd immunity[5].